Immunome FY 2025 Results Set Up A High Growth, High Loss Story

Immunome (IMNM) has just reported FY 2025 first half results with revenue of US$6.9 million and a basic EPS loss of US$1.02 per share, alongside a net income loss of US$85.0 million, keeping margins firmly in negative territory. The company has seen revenue move from US$3.4 million in the first half of FY 2024 to US$5.6 million in the second half, and now to US$6.9 million in the first half of FY 2025. Over the same periods EPS has remained loss making. As a result, the current release places revenue growth potential against a backdrop of ongoing heavy losses and margin pressure that investors will be weighing carefully.

With the numbers on the table, the next step is to see how this mix of growing revenue and persistent losses lines up with the widely followed narratives around Immunome, and where those stories might need updating.

Losses Stay Heavy With US$212.4 Million TTM Net Loss

• On a trailing twelve month basis, Immunome reported total revenue of US$12.6 million and a net income loss of US$212.4 million, so the business is still firmly loss making even as revenue builds from the US$3.4 million level seen in the first half of FY 2024.
• Critics highlight a bearish concern that losses can drag on for years, and the data points in that direction, with losses rising at about 51.3% per year over the past five years and no profitability expected over the next three years, even as revenue is forecast to grow about 53.05% per year.
  • That combination of a US$212.4 million trailing loss and a forecast period where earnings are still expected to be negative heavily supports the cautious view that the path to break even is not yet visible in the reported numbers.
  • At the same time, the move from a US$165.6 million loss in the first half of FY 2024 to US$85.0 million in the first half of FY 2025 shows that individual periods can look different, so bears need to pay attention to how quickly that trajectory changes rather than assuming a straight line.

53.05% Revenue Growth Forecast Versus Persistent Losses

• Analysts are looking for revenue to grow about 53.05% per year and to run ahead of the 10.2% per year figure cited for the wider US market, which sits against a history where trailing twelve month revenue is US$12.6 million and margins are still negative.
• Supporters point to a bullish angle that strong top line growth can set up long term value, and the numbers play into that story, with revenue stepping from US$3.4 million in the first half of FY 2024 to US$5.6 million in the second half and then US$6.9 million in the first half of FY 2025, even though net income has stayed in loss territory across all those periods.
  • That mix of growing revenue and negative earnings challenges bulls to explain how and when those losses, such as the US$85.0 million loss in the latest half, might narrow enough for the growth to translate into a different margin profile.
  • At the same time, the 53.05% revenue growth forecast and the fact that losses are expected to continue show that the bullish case is built more on future scale than on any current sign of profitability in the figures.

Valuation Gap, Dilution And A 54.7% Implied Upside

• Immunome shares trade at US$22.52 while analysts point to a price target of US$34.85 and a DCF fair value of US$198.06, so the stock is described as about 88.6% below that DCF fair value and carrying a P/B of 4x versus 2.6x for the US Biotechs industry and 8.6x for peers after a year that also included major shareholder dilution.
• What stands out in the bullish narrative is that analysts see around 54.7% upside from the current price, yet the same dataset flags substantial dilution and ongoing losses, which gives investors a clear tension to think about.
  • On one side, the implied upside from US$22.52 to US$34.85 and the large gap to the US$198.06 DCF fair value align with the view that the market is not fully pricing in the 53.05% revenue growth forecast.
  • On the other, a 4x P/B that is above the 2.6x industry average plus a year of heavy dilution and a US$212.4 million trailing loss support the more bearish argument that valuation signals are mixed and highly dependent on those growth assumptions playing out.

Analysts are trying to reconcile that large gap between current price, targets and DCF fair value with the heavy losses and dilution history, and you can see how both the optimistic and cautious cases are leaning on the same set of numbers.📊 Read the what the Community is saying about Immunome.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Immunome's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of growth hopes and heavy losses leaves you undecided, now may be a good time to review the numbers yourself and form your own view, starting with 3 key rewards and 2 important warning signs.

See What Else Is Out There

Immunome combines heavy losses, ongoing dilution and a US$212.4 million trailing net loss, with no clear line of sight to profitability in the forecasts.

If you want some balance to that risk profile, take a look at our 77 resilient stocks with low risk scores that focus on businesses with steadier fundamentals and fewer potential shocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.